In a phase 1 clinical trial, 3 × 107 or 3 × 108 c-MET CAR-T cells constructed via mRNA were administered to six patients with metastatic BC and showed well-tolerated results with inflammatory responses. The gene discussed is MET; the disease is breast cancer.